The Unique Power of CAR-iNKT Cells to Overcome the Barriers That Limit Traditional Cell Therapies – MiNK Therapeutics
MiNK Therapeutics shared a post on LinkedIn about their recent publication in Frontiers in Immunology by Magdalena Niedzielska et al.:
“We’re excited to share our latest publication in Frontiers in Immunology, highlighting the unique power of CAR-iNKT cells to overcome the barriers that limit traditional cell therapies – especially in solid tumors.
Unlike conventional CAR-T, iNKT cells combine precision targeting, innate immune activation, and off-the-shelf accessibility. Recent case reports and ongoing trials continue to demonstrate encouraging activity in heavily pre-treated, immunotherapy-resistant cancers.
This paper reinforces the promise of MiNK’s platform to reshape the future of cancer treatment.
Read the publication.”
Title: CAR-iNKT cells: redefining the frontiers of cellular immunotherapy
Journal: Frontiers in Immunology
Authors: Magdalena Niedzielska, Amy Chalmers, Martyna C. Popis, Efrat Altman-Sharoni, Stephen Addis, Rebekka Beulen, Nils-Petter Rudqvist, Eleni Chantzoura, Marco A. Purbhoo, Dhan Chand, Mark A. Exley
More posts featuring MiNK Therapeutics on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023